Abstract 74P
Background
ERBB2, a receptor tyrosine kinase, is commonly affected by mutations, amplifications, and overexpression in various types of cancers. Drugs targeting ERBB2 are gradually being promoted to various types of cancer. However, the variation of ERBB2 in Chinese population and the relationship between ERBB2 high expression abnormalities and the tumor immune microenvironment remains unclear.
Methods
We utilized genomic data from over 10,000 pan-cancer Chinese populations in CbioPortal to detect somatic mutations and copy number variations. We also performed RNA sequencing date in TCGA (pan-cancer Atlas studies) to determine ERBB2 expression in diverse cancer types and evaluate the immune gene characteristics and content of tumor-infiltrating immune cell populations.
Results
A total of 309 ERBB2 amplifications, 169 ERBB2 substitution or insertion deletions, and 28 ERBB2 fusions or rearrangements were detected in 10,194 patients. The ERBB2 amplification rate of breast cancer (23.84%), gallbladder cancer (13.75%) and urothelium cancer (8.33%) ranked the top three among all cancer types. Among the co-mutated genes with ERBB2 mutations, TP53 (68.8%), CDK12 (34.7%), and RARA (18.7%) have the highest proportion of mutations. Furthermore, among 10,967 RNA datasets in TCGA, breast cancer, esophageal squamous cell carcinoma, and gastric adenocarcinoma displayed the highest average expression levels of ERBB2. Patients with high ERBB2 expression exhibited similar TMB values to those with low ERBB2 expression. However, in breast cancer, colon cancer, lung adenocarcinoma and lung squamous carcinoma, ERBB2 high expression was significantly associated with a higher proportion of activated mast cells, monocytes, and regulatory T cells, while the percentage of resting mast cells and M1 macrophages was notably lower.
Conclusions
Our study identified ERBB2 variation patterns among a cohort of Chinese solid tumor patients and demonstrated that ERBB2 abnormality high expression is associated with an activated immune system and a stronger inflammatory response. Our findings offer insights into the potential benefits of using immune checkpoint inhibitors for this type of patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09